Analyst Rating Update on Foundation Medicine (FMI)

Foundation Medicine (FMI) has an average broker rating of 2.33, which is interpreted as a Buy, as rated by 3 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Foundation Medicine (FMI) : The highest short term price target forecast on Foundation Medicine (FMI) is $23 and the lowest target price is $15. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $19 with a standard deviation of $5.66.

Company shares have received an average consensus rating of Hold for the current week


Foundation Medicine (NASDAQ:FMI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $21.29 and $18.53 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.48. The buying momentum continued till the end and the stock did not give up its gains. It closed at $24.18, notching a gain of 4.13% for the day. The total traded volume was 957,496 . The stock had closed at $23.22 on the previous day.

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patients individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products, FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and various sarcomas and pediatric cancers, are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.